Skip to main content
Erschienen in:

01.12.2010

Heterogeneous Postprandial Lipoprotein Responses in the Metabolic Syndrome, and Response to Fenofibrate Therapy

verfasst von: Robert S. Rosenson, Irene B. Helenowski, Christine C. Tangney

Erschienen in: Cardiovascular Drugs and Therapy | Ausgabe 5-6/2010

Einloggen, um Zugang zu erhalten

Abstract

Background

Hypertriglyceridemia subjects with metabolic syndrome exhibit variable postprandial triglyceride responses. We investigate the effects of fenofibrate therapy on postprandial triglyceride-containing lipoproteins in subjects with early (3.5 h) versus late (8 h) postprandial triglyceride responses.

Methods

Fifty-five subjects with fasting hypertriglyceridemia (≥1.7 mmol/L (150 mg/ dL) and <5.8 mmol/L (500 mg/dL)) and ≥2 Adult Treatment Panel III criteria of the metabolic syndrome were randomized to daily fenofibrate (160 mg/d) or placebo for 12 weeks in a double-blind controlled clinical trial. A standardized fat load (50 g/m2) was given orally after a 12 h fast. Blood specimens were obtained at 0 h (fasting), 3.5 h, and 8 h after the test meal. Analysis is confined to the 53 subjects with clearly identifiable early or late triglyceride peaks prior to therapy.

Results

Fenofibrate was more effective in late peakers (n = 8) when compared to early peakers (n = 15) with respect to reducing postprandial triglyceride concentrations (−67% vs. −34%, p = 0.0024) and large VLDL (−76% vs. −31%, p = 0.0016), and increasing total HDL particles (20% vs. 11%, p = 0.008) and large HDL particles (185% vs. 88%, p = 0.003). On fenofibrate therapy, 100% of those initially designated as late peakers were reclassified as early peakers; 47% of late peakers assigned to placebo were reclassified as early peakers.

Conclusions

Late postprandial triglyceride responders have attenuated clearance of large VLDL particles, but they were more responsive to fenofibrate.
Literatur
1.
Zurück zum Zitat Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, et al. Triglycerides and the risk of coronary heart disease: 10.158 incident cases among 262, 525 participants in 29 Western prospective studies. Circulation. 2007;115:450–8.PubMedCrossRef Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, et al. Triglycerides and the risk of coronary heart disease: 10.158 incident cases among 262, 525 participants in 29 Western prospective studies. Circulation. 2007;115:450–8.PubMedCrossRef
2.
Zurück zum Zitat Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007;298:299–308.PubMedCrossRef Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007;298:299–308.PubMedCrossRef
3.
Zurück zum Zitat Stensvold I, Tverdal A, Urdal P, Graff-Iversen S. Non-fasting serum triglyceride concentration and mortality from coronary heart disease and any cause in middle aged Norwegian women. BMJ. 1993;307:1318–22.PubMedCrossRef Stensvold I, Tverdal A, Urdal P, Graff-Iversen S. Non-fasting serum triglyceride concentration and mortality from coronary heart disease and any cause in middle aged Norwegian women. BMJ. 1993;307:1318–22.PubMedCrossRef
4.
Zurück zum Zitat Stampfer MJ, Krauss RM, Ma J, Blanche PJ, Holl LG, Sacks FM, et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA. 1996;276:882–8.PubMedCrossRef Stampfer MJ, Krauss RM, Ma J, Blanche PJ, Holl LG, Sacks FM, et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA. 1996;276:882–8.PubMedCrossRef
5.
Zurück zum Zitat Iso H, Naito Y, Sato S, Kitamura A, Okamura T, Sankai T, et al. Serum triglycerides and risk of coronary heart disease among Japanese men and women. Am J Epidemiol. 2001;153:490–9.PubMedCrossRef Iso H, Naito Y, Sato S, Kitamura A, Okamura T, Sankai T, et al. Serum triglycerides and risk of coronary heart disease among Japanese men and women. Am J Epidemiol. 2001;153:490–9.PubMedCrossRef
6.
Zurück zum Zitat Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA. 2007;298:309–16.PubMedCrossRef Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA. 2007;298:309–16.PubMedCrossRef
7.
Zurück zum Zitat Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet. 2010;375:1634–9.CrossRef Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet. 2010;375:1634–9.CrossRef
8.
Zurück zum Zitat Kofoed SC, Grønholdt M-LM, Bismuth J, Wilhjelm JE, Sillesen H, Nordestgaard BG. Echolucent, rupture-prone carotid plaques associated with elevated triglyceride-rich lipoproteins, particularly in women. J Vasc Surg. 2002;36:783–92.PubMed Kofoed SC, Grønholdt M-LM, Bismuth J, Wilhjelm JE, Sillesen H, Nordestgaard BG. Echolucent, rupture-prone carotid plaques associated with elevated triglyceride-rich lipoproteins, particularly in women. J Vasc Surg. 2002;36:783–92.PubMed
9.
Zurück zum Zitat Rosenson RS, Wolff DA, Huskin AL, Helenowski IB, Rademaker AW. Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome. Diab Care. 2007;30:1945–51.CrossRef Rosenson RS, Wolff DA, Huskin AL, Helenowski IB, Rademaker AW. Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome. Diab Care. 2007;30:1945–51.CrossRef
10.
Zurück zum Zitat Executive Summary of The Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 285: 2486-2497. Executive Summary of The Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 285: 2486-2497.
11.
Zurück zum Zitat Tangney CC, Hafner JM, McQuiston BD, Domas AJ, Rosenson RS. Postprandial changes in plasma and serum viscosity and plasma lipids and lipoproteins after an acute test meal. Am J Clin Nutr. 1997;65:36–40.PubMed Tangney CC, Hafner JM, McQuiston BD, Domas AJ, Rosenson RS. Postprandial changes in plasma and serum viscosity and plasma lipids and lipoproteins after an acute test meal. Am J Clin Nutr. 1997;65:36–40.PubMed
12.
Zurück zum Zitat Jeyarajah EJ, Cromwell WC, Otvos JD. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med. 2006;26:847–70.PubMedCrossRef Jeyarajah EJ, Cromwell WC, Otvos JD. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med. 2006;26:847–70.PubMedCrossRef
13.
Zurück zum Zitat Wallace T, Matthews D. The assessment of insulin resistance in man. Diabet Med. 2002;19:527–34.PubMedCrossRef Wallace T, Matthews D. The assessment of insulin resistance in man. Diabet Med. 2002;19:527–34.PubMedCrossRef
14.
Zurück zum Zitat Lai C-Q, Arnett DK, Corella D, Straka RJ, Tsai MY, Peacock JM, et al. Fenofibrate effect on triglyceride and postprandial response of apolipoprotein A5 Variants: The GOLDN Study. Arterioscler Thromb Vasc Biol. 2007;27:1417–25.PubMedCrossRef Lai C-Q, Arnett DK, Corella D, Straka RJ, Tsai MY, Peacock JM, et al. Fenofibrate effect on triglyceride and postprandial response of apolipoprotein A5 Variants: The GOLDN Study. Arterioscler Thromb Vasc Biol. 2007;27:1417–25.PubMedCrossRef
15.
Zurück zum Zitat Lai C-Q, Corella D, Demissie S, Cupples LA, Adiconis X, Zhu Y, et al. Dietary intake of n-6 fatty acids modulates effect of apolipoprotein A5 gene on plasma fasting triglycerides, remnant lipoprotein concentrations, and lipoprotein particle size: The Framingham Heart Study. Circulation. 2006;113:2062–70.PubMedCrossRef Lai C-Q, Corella D, Demissie S, Cupples LA, Adiconis X, Zhu Y, et al. Dietary intake of n-6 fatty acids modulates effect of apolipoprotein A5 gene on plasma fasting triglycerides, remnant lipoprotein concentrations, and lipoprotein particle size: The Framingham Heart Study. Circulation. 2006;113:2062–70.PubMedCrossRef
16.
Zurück zum Zitat Baass A, Dubuc G, Tremblay M, Delvin EE, O’Loughlin J, Levy E, et al. Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents. Clin Chem. 2009;55:1637–45.PubMedCrossRef Baass A, Dubuc G, Tremblay M, Delvin EE, O’Loughlin J, Levy E, et al. Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents. Clin Chem. 2009;55:1637–45.PubMedCrossRef
17.
Zurück zum Zitat Lambert G, Jarnoux A-L, Pineau T, Pape O, Chetiveaux M, Laboisse C, et al. Fasting induces hyperlipidemia in mice overexpressing proprotein convertase subtilisin kexin type 9: lack of modulation of very-low density lipoprotein hepatic output by the low-density lipoprotein receptor. Endocrinology. 2006;147:4985–95.PubMedCrossRef Lambert G, Jarnoux A-L, Pineau T, Pape O, Chetiveaux M, Laboisse C, et al. Fasting induces hyperlipidemia in mice overexpressing proprotein convertase subtilisin kexin type 9: lack of modulation of very-low density lipoprotein hepatic output by the low-density lipoprotein receptor. Endocrinology. 2006;147:4985–95.PubMedCrossRef
18.
Zurück zum Zitat Dubuc G, Tremblay M, Pare G, Jacques H, Hamelin J, Benjannet S, et al. A new method for measurement of total plasma PCSK9: clinical applications. J Lipid Res. 2010;51:140–9.PubMedCrossRef Dubuc G, Tremblay M, Pare G, Jacques H, Hamelin J, Benjannet S, et al. A new method for measurement of total plasma PCSK9: clinical applications. J Lipid Res. 2010;51:140–9.PubMedCrossRef
19.
Zurück zum Zitat Le May C, Kourimate S, Langhi C, Chetiveaux M, Jarry A, Comera C, et al. Proprotein convertase subtilisin kexin type 9 null mice are protected from postprandial triglyceridemia. Arterioscler Thromb Vasc Biol. 2009;29:684–90.PubMedCrossRef Le May C, Kourimate S, Langhi C, Chetiveaux M, Jarry A, Comera C, et al. Proprotein convertase subtilisin kexin type 9 null mice are protected from postprandial triglyceridemia. Arterioscler Thromb Vasc Biol. 2009;29:684–90.PubMedCrossRef
20.
Zurück zum Zitat Kourimate S, Le May C, Langhi C, Jarnoux AL, Ouguerram K, Zair Y, et al. Dual mechanism for the fibrate-mediated repression of proprotein convertase subtilisn/kexin type 9. J Biol Chem. 2008;283:9666–73.PubMedCrossRef Kourimate S, Le May C, Langhi C, Jarnoux AL, Ouguerram K, Zair Y, et al. Dual mechanism for the fibrate-mediated repression of proprotein convertase subtilisn/kexin type 9. J Biol Chem. 2008;283:9666–73.PubMedCrossRef
21.
Zurück zum Zitat Lewis GF, Uffelman KD, Szeto LW, Weller B, Steiner G. Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans. J Clin Invest. 1995;95:158–66.PubMedCrossRef Lewis GF, Uffelman KD, Szeto LW, Weller B, Steiner G. Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans. J Clin Invest. 1995;95:158–66.PubMedCrossRef
22.
Zurück zum Zitat Baldeweg SE, Golay A, Natali A, Balkau B, Del Prato S, Coppack SW. Insulin resistance, lipid and fatty acid concentrations in 867 healthy Europeans. European Group for the Study of Insulin Resistance (EGIR). Eur J Clin Invest. 2000;30:45–52.PubMedCrossRef Baldeweg SE, Golay A, Natali A, Balkau B, Del Prato S, Coppack SW. Insulin resistance, lipid and fatty acid concentrations in 867 healthy Europeans. European Group for the Study of Insulin Resistance (EGIR). Eur J Clin Invest. 2000;30:45–52.PubMedCrossRef
23.
Zurück zum Zitat McKeigue PM, Laws A, Chen YD, Marmot MG, Reaven GM. Relation of plasma triglyceride and apoB levels to insulin-mediated suppression of nonesterified fatty acids. Possible explanation for sex differences in lipoprotein pattern. Arterioscler Thromb. 1993;13:1187–92.PubMed McKeigue PM, Laws A, Chen YD, Marmot MG, Reaven GM. Relation of plasma triglyceride and apoB levels to insulin-mediated suppression of nonesterified fatty acids. Possible explanation for sex differences in lipoprotein pattern. Arterioscler Thromb. 1993;13:1187–92.PubMed
24.
Zurück zum Zitat Laws A, Hoen HM, Selby JV, Saad MF, Haffner SM, Howard BV. Differences in insulin suppression of free fatty acid levels by gender and glucose tolerance status: relation to plasma triglyceride and apolipoprotein B concentrations. Arterioscler Thromb Vasc Biol. 1997;17:64–71.PubMed Laws A, Hoen HM, Selby JV, Saad MF, Haffner SM, Howard BV. Differences in insulin suppression of free fatty acid levels by gender and glucose tolerance status: relation to plasma triglyceride and apolipoprotein B concentrations. Arterioscler Thromb Vasc Biol. 1997;17:64–71.PubMed
25.
Zurück zum Zitat Arii K, Suehiro T, Yamamoto M, Ito H, Hashimoto K. Suppression of plasma cholesteryl ester transfer protein activity in acute hyperinsulinemia and effect of plasma nonesterified fatty acid. Metabolism. 1997;46:1166–70.PubMedCrossRef Arii K, Suehiro T, Yamamoto M, Ito H, Hashimoto K. Suppression of plasma cholesteryl ester transfer protein activity in acute hyperinsulinemia and effect of plasma nonesterified fatty acid. Metabolism. 1997;46:1166–70.PubMedCrossRef
26.
Zurück zum Zitat Lagrost L, Florentin E, Guyard-Dangremont V, Athias A, Gandjini H, Lallemant C, et al. Evidence for nonesterified fatty acids as modulators of neutral lipid transfers in normolipidemic human plasma. Arterioscler Thromb Vasc Biol. 1995;15:1388–96.PubMed Lagrost L, Florentin E, Guyard-Dangremont V, Athias A, Gandjini H, Lallemant C, et al. Evidence for nonesterified fatty acids as modulators of neutral lipid transfers in normolipidemic human plasma. Arterioscler Thromb Vasc Biol. 1995;15:1388–96.PubMed
27.
Zurück zum Zitat Grundy SM, Mok HY. Chylomicron clearance in normal and hyperlipidemic man. Metabolism. 1976;25:1225–39.PubMedCrossRef Grundy SM, Mok HY. Chylomicron clearance in normal and hyperlipidemic man. Metabolism. 1976;25:1225–39.PubMedCrossRef
Metadaten
Titel
Heterogeneous Postprandial Lipoprotein Responses in the Metabolic Syndrome, and Response to Fenofibrate Therapy
verfasst von
Robert S. Rosenson
Irene B. Helenowski
Christine C. Tangney
Publikationsdatum
01.12.2010
Verlag
Springer US
Erschienen in
Cardiovascular Drugs and Therapy / Ausgabe 5-6/2010
Print ISSN: 0920-3206
Elektronische ISSN: 1573-7241
DOI
https://doi.org/10.1007/s10557-010-6264-6

Weitere Artikel der Ausgabe 5-6/2010

Cardiovascular Drugs and Therapy 5-6/2010 Zur Ausgabe

EditorialNotes

President’s Page

Neu im Fachgebiet Kardiologie

Nach dem Nitrospray fünf Minuten mit der Kardio-CT warten!

19.07.2024 Koronare Herzerkrankung Nachrichten

Nach Verabreichung von sublingualem Nitrospray vor einer CT-Koronarangiografie sollte man unbedingt die in Leitlinien empfohlene Wartezeit einhalten, rät ein kardiologisches Team aus Belgien.

Welche Antikoagulation bei Vorhofflimmern und Leberzirrhose?

19.07.2024 Leberzirrhose Nachrichten

Bei einer Auswertung von US-Versicherungsdaten ging es um die Frage, welche Antikoagulation –  Apixaban, Rivaroxaban oder Warfarin – bei Personen mit Leberzirrhose und Vorhofflimmern unterm Strich die beste Prophylaxe-Option ist.     

Mehrgefäßstenosen einzeitig oder zweizeitig eröffnen?

18.07.2024 Gefäßstenosen Nachrichten

Nach einem Herzinfarkt mit Mehrgefäßerkrankung sind bessere Ergebnisse zu erwarten, wenn alle stenotischen Abschnitte revaskularisiert werden. Sollte das in einer oder in mehreren Sitzungen geschehen? Eine Metaanalyse gibt eine klare Antwort.

Erste zielgerichtete Therapie zur Behandlung der hypertrophen obstruktiven Kardiomyopathie

18.07.2024 Kardiomyopathie Nachrichten

Mit Mavacamten von Bristol Myers Squibb ist erstmals eine zielgerichtete Therapie der hypertrophen obstruktiven Kardiomyopathie (HOCM) verfügbar. Der Myosin-Inhibitor verhindert die bei HOCM übermäßige Bildung von Aktin-Myosin-Querbrücken und verbessert die Symptomatik und die Lebensqualität von Betroffenen.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.